A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
442 enrolled
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
233 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
Phase 1/2 Recruiting
188 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Phase 1/2 Recruiting
60 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
FONTANA
Phase 1/2 Recruiting
506 enrolled
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Phase 1/2 Recruiting
160 enrolled
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/2 Recruiting
205 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/2 Recruiting
460 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Phase 1/2 Recruiting
266 enrolled
BetaBart
Phase 1/2 Recruiting
61 enrolled
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
Phase 1/2 Recruiting
100 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Phase 1/2 Recruiting
890 enrolled
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/2 Recruiting
350 enrolled
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Phase 1/2 Recruiting
612 enrolled
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
430 enrolled
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/2 Recruiting
200 enrolled
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Phase 1/2 Recruiting
38 enrolled
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Phase 1/2 Recruiting
540 enrolled
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Phase 1/2 Recruiting
300 enrolled
EndoMAP
Phase 1/2 Recruiting
148 enrolled
ERADIC8
Phase 1/2 Recruiting
120 enrolled
START-001
Phase 1/2 Recruiting
365 enrolled
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
115 enrolled
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/2 Recruiting
275 enrolled
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Phase 1/2 Recruiting
37 enrolled
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Phase 1/2 Recruiting
282 enrolled
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Phase 1/2 Recruiting
200 enrolled
ATAPEMBRO
Phase 1/2 Recruiting
47 enrolled